RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MARTINELLI E
Collezione AOU Città della Salute di Torino

Items : 6

Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. in Targeted oncology / Target Oncol. 2024 May;19(3):359-370. doi: 10.1007/s11523-024-01060-1. Epub 2024 May 1.

2024
ASL Biella
AOU Città della Salute di Torino

Aldrighetti L; Ratti F; De Rosa A; Zanuso V; Niger M; Fornaro L; Rossari F; Satolli MA; Garattini SK; Brandi G; Brunetti O; Leone F; Diana A; Pirrone C; Toma I; Pretta A; Landriscina M; Lorenzo A; Gusmaroli E; Bergamo F; Balsano R; Winchler C; Salani F; Formica V; Schirripa M; Aprile G; Garajova I; Martinelli E; Rapposelli IG; et alii...

Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 Aug 1;42(22):2637-2644. doi: 10.1200/JCO.23.02728. Epub 2024 Jun 12.

2024
AOU Città della Salute di Torino

Antoniotti C; Rossini D; Pietrantonio F; Salvatore L; Lonardi S; Tamberi S; Marmorino F; Moretto R; Prisciandaro M; Tamburini E; Tortora G; Passardi A; Bergamo F; Raimondi A; Ritorto G; Borelli B; Conca V; Ugolini C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Boni L; Galon J; Cremolini C;

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2022 Jul;23(7):876-887. doi: 10.1016/S1470-2045(22)00274-1. Epub 2022 May 27.

2022
AOU Città della Salute di Torino

Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; et alii...

Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer. in Future oncology (London, England) / Future Oncol. 2021 Jun;17(18):2315-2324. doi: 10.2217/fon-2020-1278. Epub 2021 Mar 5.

2021
AOU Città della Salute di Torino

Tamburini E; Racca P; Personeni N; Martinelli E; Latiano TP; Giuliani F; Garufi C; Frassineti GL; Costanzo FD; Bartolomeo MD; Bordonaro R; Blasi L; Bergamo F; Banzi MC; Barone CA; Zaniboni A; Tonini G; Besse MG; Spione M; Falcone A;

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. in The oncologist / Oncologist. 2019 Oct;24(10):1395-1402. doi: 10.1634/theoncologist.2018-0785. Epub 2019 Apr 5.

2019
AOU Città della Salute di Torino

Bardelli A; Zagonel V; Marrapese G; Ciardiello F; Vaghi C; Martino C; Bonoldi E; Valtorta E; Racca P; Tosi F; Borelli B; Martinelli E; Bergamo F; Fenocchio E; Leone F; Lonardi S; Ghezzi S; Amatu A; Porcu L; Sartore-Bianchi A; Trusolino L; Torri V; Marsoni S; Siena S;

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20.

2016
AOU Città della Salute di Torino

Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; et alii...